CN Mobile Logo

Search form


Zoladex Gets Indication for Advanced Breast Ca

Zoladex Gets Indication for Advanced Breast Ca

WILMINGTON, Del--Zoladex (goserelin acetate implant), Zeneca Pharmaceuticals' gonadotropin-releasing-hormone (GnRH) agonist, has received approval for use in the treatment of advanced breast cancer in premenopausal and perimenopausal women.

The agent was introduced in the United States for the treatment of advanced prostate cancer in 1989 and for the treatment of endometriosis in 1993.

Zoladex, given by injection once a month, acts on the pituitary gland to cause decreased production of estrogen by the ovaries. This lowers serum estrogen levels to concentrations typical of postmenopausal women, reducing estrogen stimulation of breast tumor growth.

The new indication is based on results of clinical trials involving more than 800 women in North America and Europe, showing response rates and survival benefits comparable to those achieved by oophorectomy, the company said.

By clicking Accept, you agree to become a member of the UBM Medica Community.